Nutra Pharma (NPHC) Stock Price
Nutra Pharma Price
Over the last 19 years Nutra Pharma grew revenue by 16.8% annually, reaching 385,307.00 USD. For Nutra Pharma, the net margin of -531.4% is up versus -13,399.0% a few years ago.
Nutra Pharma stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Nutra Pharma business model & stock analysis
Frequently asked questions about Nutra Pharma
The business model of Nutra Pharma Corp is focused on the development, licensing, and commercialization of novel therapeutic drugs and products for various medical needs. Nutra Pharma Corp specializes in the research and development of treatments for multiple sclerosis (MS), HIV/AIDS, adrenomyeloneuropathy (AMN), and pain management. Through its subsidiary, ReceptoPharm, Inc., Nutra Pharma Corp utilizes its proprietary drug discovery platform to identify and advance potential drug candidates. Furthermore, by leveraging strategic partnerships and collaborations, Nutra Pharma Corp aims to bring innovative and effective pharmaceutical products to market, addressing unmet medical needs globally.
Nutra Pharma Corp is primarily active in the pharmaceutical industry.
The main competitors of Nutra Pharma Corp in the market include pharmaceutical companies such as Johnson & Johnson, Pfizer, and GlaxoSmithKline.
Nutra Pharma Corp, founded in 2000, is a pharmaceutical company based in Florida, USA. It specializes in the development and commercialization of innovative pharmaceutical and natural products for the management of pain and neurological disorders. The company has a strong focus on researching and identifying potential treatments derived from rare and medicinal plants. Nutra Pharma Corp has a diverse product portfolio, including over-the-counter products, prescription-based pain relievers, and therapies for multiple sclerosis and HIV-related neuropathic pain. With a commitment to providing effective and safe treatment options, Nutra Pharma Corp continues to forge ahead in the pharmaceutical industry.
Nutra Pharma Corp, a renowned pharmaceutical company, has achieved significant milestones throughout its existence. Some notable accomplishments include the development and FDA registration of Nyloxin®, an over-the-counter pain reliever for chronic pain sufferers. Additionally, Nutra Pharma Corp has successfully obtained patents for its innovative technologies, such as the extraction and stabilization of venom from poisonous snakes for medicinal use. With its dedication to scientific research and innovation, Nutra Pharma Corp continues to spearhead advancements in the pharmaceutical industry, demonstrating its commitment to improving the lives of individuals dealing with various medical conditions.
Nutra Pharma Corp is primarily present in the United States.
Nutra Pharma Corp is a leading pharmaceutical company dedicated to providing innovative solutions for pain management, neurological disorders, and autoimmune diseases. With a strong focus on research and development, Nutra Pharma strives to deliver cutting-edge treatments and therapies that improve the quality of life for patients. The company values integrity, transparency, and a commitment to excellence in all aspects of their operations. With its extensive product portfolio and dedication to improving healthcare, Nutra Pharma Corp is positioned as a trusted and reliable partner in the pharmaceutical industry.
Converted at the current exchange rate, the Nutra Pharma share trades at 0.00 EUR (0.00 USD).
Nutra Pharma Corp is a US pharmaceutical development company founded in 2000 by former Goldman Sachs broker Rik Deitsch. The company, headquartered in Coral Springs, Florida, operates in various areas including pharmaceutical development, patent licensing, product distribution, and the production of biological products. They specialize in researching treatment options for autoimmune diseases, particularly focusing on multiple sclerosis (MS), HIV, and arthritis. They also license patents for the use of the compounds Cobroxin and Nyloxin, derived from snake venom, for pain therapy. Nutra Pharma Corp distributes products for pain relief and immune support, such as Nyloxin and Pet Pain-Away. They also manufacture homeopathic products, specifically the "Nyloxin Homeopathy" for chronic pain treatment. Overall, Nutra Pharma Corp has achieved success in each area of their business model, making them a promising company.
The revenue cannot currently be calculated for Nutra Pharma.
The profit cannot currently be calculated for Nutra Pharma.
The P/E ratio cannot be calculated for Nutra Pharma at the moment.
The P/S cannot be calculated for Nutra Pharma currently.
The Eulerpool Quality Score for Nutra Pharma is 1/10.
The ISIN of Nutra Pharma is US67060U2087. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Nutra Pharma is NPHC. The ticker symbol is used to trade Nutra Pharma shares on the stock exchange.
Nutra Pharma stock
Nutra Pharma Peer Group
Nutra Pharma FIGI
All fundamentals and in-depth analysis of Nutra Pharma
Our stock analysis for Nutra Pharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nutra Pharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.